DNA

PetMeds Announces Holiday Collection: Wellness-Focused Gifts for Pets and the People Who Love Them

DELRAY BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq:…

2 months ago

PetMeds Announces Holiday Collection: Wellness-Focused Gifts for Pets and the People Who Love Them

DELRAY BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq:…

2 months ago

Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors

MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H…

2 months ago

Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors

MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H…

2 months ago

Rakovina Therapeutics Announces Upcoming Webinar with Variational AI

From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer TherapiesVANCOUVER, British Columbia, Dec.…

2 months ago

Rakovina Therapeutics Announces Upcoming Webinar with Variational AI

From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer TherapiesVANCOUVER, British Columbia, Dec.…

2 months ago

Bioxodes raises €5.5 million Series A extension to continue preparations for pivotal trial of breakthrough stroke candidate

Newton Biocapital enters as new investor, strong participation of existing investorsPivotal Phase 2b trial initiation in 2027 of BIOX-101 to…

2 months ago

Bioxodes raises €5.5 million Series A extension to continue preparations for pivotal trial of breakthrough stroke candidate

Newton Biocapital enters as new investor, strong participation of existing investorsPivotal Phase 2b trial initiation in 2027 of BIOX-101 to…

2 months ago

Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)

BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the…

2 months ago

Over 20 Studies of InnoCare’s Orelabrutinib Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)

BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the…

2 months ago
Show more Posts
Show previous Posts